"xaliproden" meaning in All languages combined

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "xaliproden (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2000, Mark B. Bromberg, Supplements to Clinical Neurophysiology, →ISBN:",
          "text": "The accuracy and reproducibility of this modification has been discussed in Chapter 8. We have used MPS MUNE with tracking to follow a group of ALS patients enrolled in a multicenter controlled trial of xaliproden with and without riluzole. Data analysis is ongoing and will be the subject of a future publication, but summary results of an interim analysis are described below.",
          "type": "quote"
        },
        {
          "ref": "2008 April 15, P. Murali Doraiswamy, M.D., Lisa P. Gwyther, M.S.W., Tina Adler, The Alzheimer's Action Plan: The Experts' Guide to the Best Diagnosis and Treatment for Memory Problems, St. Martin's Press, →ISBN, page 173:",
          "text": "... Xaliproden. As with the drug cerebrolysin discussed above, xaliproden mimics the actions of NGFs. It was initially studied without success in Lou Gehrig's disease, a condition, like Alzheimer's, that involves progressive brain damage[…]",
          "type": "quote"
        },
        {
          "ref": "2017 November 14, Angeles Canales, Biophysical Techniques in Drug Discovery, Royal Society of Chemistry, →ISBN, page 141:",
          "text": "The results showed that the polymorphism between xaliproden Forms I and III mostly concerns the degree of freedom of the CF3 group, higher in Form III than in Form I, and they clarified the status of Form III, which could then be assigned to a well-defined polymorph of xaliproden.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A drug which acts as a 5HT1A agonist, proposed for use in the treatment of several neurodegenerative conditions including Alzheimer's disease."
      ],
      "id": "en-xaliproden-en-noun-qvl6Qmal",
      "links": [
        [
          "drug",
          "drug"
        ],
        [
          "agonist",
          "agonist"
        ],
        [
          "neurodegenerative",
          "neurodegenerative"
        ],
        [
          "Alzheimer's disease",
          "Alzheimer's disease"
        ]
      ],
      "tags": [
        "uncountable"
      ],
      "wikipedia": [
        "xaliproden"
      ]
    }
  ],
  "sounds": [
    {
      "audio": "LL-Q1860 (eng)-Flame, not lame-xaliproden.wav",
      "mp3_url": "https://upload.wikimedia.org/wikipedia/commons/transcoded/d/da/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav.mp3",
      "ogg_url": "https://upload.wikimedia.org/wikipedia/commons/transcoded/d/da/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav.ogg"
    },
    {
      "ipa": "/zəˈlɪpɹədɛn/"
    }
  ],
  "word": "xaliproden"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "xaliproden (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries"
      ],
      "examples": [
        {
          "ref": "2000, Mark B. Bromberg, Supplements to Clinical Neurophysiology, →ISBN:",
          "text": "The accuracy and reproducibility of this modification has been discussed in Chapter 8. We have used MPS MUNE with tracking to follow a group of ALS patients enrolled in a multicenter controlled trial of xaliproden with and without riluzole. Data analysis is ongoing and will be the subject of a future publication, but summary results of an interim analysis are described below.",
          "type": "quote"
        },
        {
          "ref": "2008 April 15, P. Murali Doraiswamy, M.D., Lisa P. Gwyther, M.S.W., Tina Adler, The Alzheimer's Action Plan: The Experts' Guide to the Best Diagnosis and Treatment for Memory Problems, St. Martin's Press, →ISBN, page 173:",
          "text": "... Xaliproden. As with the drug cerebrolysin discussed above, xaliproden mimics the actions of NGFs. It was initially studied without success in Lou Gehrig's disease, a condition, like Alzheimer's, that involves progressive brain damage[…]",
          "type": "quote"
        },
        {
          "ref": "2017 November 14, Angeles Canales, Biophysical Techniques in Drug Discovery, Royal Society of Chemistry, →ISBN, page 141:",
          "text": "The results showed that the polymorphism between xaliproden Forms I and III mostly concerns the degree of freedom of the CF3 group, higher in Form III than in Form I, and they clarified the status of Form III, which could then be assigned to a well-defined polymorph of xaliproden.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A drug which acts as a 5HT1A agonist, proposed for use in the treatment of several neurodegenerative conditions including Alzheimer's disease."
      ],
      "links": [
        [
          "drug",
          "drug"
        ],
        [
          "agonist",
          "agonist"
        ],
        [
          "neurodegenerative",
          "neurodegenerative"
        ],
        [
          "Alzheimer's disease",
          "Alzheimer's disease"
        ]
      ],
      "tags": [
        "uncountable"
      ],
      "wikipedia": [
        "xaliproden"
      ]
    }
  ],
  "sounds": [
    {
      "audio": "LL-Q1860 (eng)-Flame, not lame-xaliproden.wav",
      "mp3_url": "https://upload.wikimedia.org/wikipedia/commons/transcoded/d/da/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav.mp3",
      "ogg_url": "https://upload.wikimedia.org/wikipedia/commons/transcoded/d/da/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav/LL-Q1860_%28eng%29-Flame%2C_not_lame-xaliproden.wav.ogg"
    },
    {
      "ipa": "/zəˈlɪpɹədɛn/"
    }
  ],
  "word": "xaliproden"
}